Highlights from The D.C. Lung Cancer Conference 2024

The D.C. Lung Cancer Conference 2024, took place on October 19th in Washington, D.C.

It provided an essential platform for clinicians to gain insights into the latest advancements in lung cancer management. This one-day multidisciplinary conference emphasized the rapid evolution of the field, highlighting significant shifts in understanding and treating this highly lethal disease.

Attendees experienced high-impact didactic lectures from internationally recognized thought leaders and esteemed faculty members, covering a comprehensive range of topics from detection to diagnosis and treatment. The conference began with an inspiring opening talk from a patient advocate, offering valuable perspectives on the patient experience.

Key sessions included updates on CT screening protocols, the appropriate use of liquid biopsies, and the interpretation of molecular testing results. Additionally, smoking cessation techniques were reviewed, underlining their importance in lung cancer prevention and management.

A dedicated section focused on optimizing multidisciplinary care for early-stage and locally advanced lung cancer, featuring discussions on modern bronchoscopy, proton beam radiation, and minimally invasive surgical approaches. The conference also addressed neoadjuvant and adjuvant systemic therapy options.

Participants gained insights into targeted therapies and immunotherapy, with sessions led by leading experts in these areas. A lively debate centered on the use of emerging biomarkers to guide treatment decisions for advanced non-small cell lung cancer (NSCLC).

Attendees benefited from interactive Q&A sessions, allowing for direct engagement with faculty, and had access to presentation materials for future reference. The D.C. Lung Cancer Conference served as a vital resource for clinicians, enhancing their knowledge and skills to improve patient care in lung cancer treatment.

Doctors shared their insights on social media:

Stephen V Liu:

“Amin Benyounes at DCLung24 describes rare fusions we can see in lung cancer – NTRK and NRG1 – and the emerging agents used to target them.”

Misty Dawn Shields:

“Wow!

DCLung24 was a phenomenal conference. Thank you Stephen V Liu for organizing a highly informative meeting! Full of great people, amazing food, and packed with fun. Bravo!”

Stephen V Liu:

“Irina Veytsman at DCLung24 discusses the advances in MET NSCLC (be sure to distinguish between mutation, amplification, and overexpression) and BRAF (with approved regimens dabrafenib and trametinib and encorafenib and binimetinib.”

Nagla Abdel Karim:

“CTLA-4 inhibition in patients with NSCLC and PDL-1 negative status or with STK11 or KEAP1 co-mutations; would it be considered? An excellent talk from Hossein Borghaei.”

Harpreet Singh:

“Thrilled to spend my Saturday with friends and colleagues to hear the latest updates on lung cancer.”

Stephen V Liu:

“Jillian Thompson, NP, discusses toxicity from immunotherapy at DCLung24. Need to remain vigilant, though most AEs are early. Those who have to stop from irAEs often do well from an efficacy standpoint. And risk of TB reactivation is real with IO.”

Chul Kim:

“Our own Joshua Reuss won the debate! Both were great. Congratulations to both for the great debates.”

For more posts like this visit oncodaily.com